Unlock instant, AI-driven research and patent intelligence for your innovation.

Broad spectrum antimicrobial formulations comprising lysozyme and methods of use thereof

A pharmaceutical preparation, lysozyme technology, applied in the field of bacterial infection accompanied by viral infection, treatment of bacterial infection in mammals, can solve unsatisfied problems

Pending Publication Date: 2022-03-01
AYBAR ECOTECHNOLOGIES CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Therefore, there is a critical and unmet need for broad-spectrum antibacterial formulations that can be used to cure or prevent diseases of a wide range of bacterial etiologies without the problems usually associated with antibacterial drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Broad spectrum antimicrobial formulations comprising lysozyme and methods of use thereof
  • Broad spectrum antimicrobial formulations comprising lysozyme and methods of use thereof
  • Broad spectrum antimicrobial formulations comprising lysozyme and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] An example was prepared to compare formulations according to the invention ("Lysodent TM ") and comparative examples (digluconate 0.12%, "chlorhexidine") in dental surgery and periodontal disease. Lysodent TM used individually in each study. Use chlorhexidine mouthwash during the operation, and use chlorhexidine (chlorhexidine + analgesics + antibiotics + anti-inflammatory drugs) during postoperative recovery follow-up.

[0131] Lysodent TM The preparation is shown in Table 1.

[0132] Table 1

[0133]

[0134] research population

[0135] Seventy subjects (gingivitis, n=40; ​​surgery, n=30) were invited to participate in this clinical trial. Subjects were selected in a manner that allowed for comparability and unbiased analysis. Clinical examiners divided subjects into two groups based on diagnosis of gingivitis or surgical candidate. Table 2 shows the selection criteria for the study population.

[0136] Table 2

[0137]

[0138] Patient Recruitment and...

example 2

[0169] For acute or chronic bacterial infections of the sinuses and lungs.

[0170] Lysosin is a composition of the present invention. While lysosin is not harmful to the mucus surface of the lungs, it can be applied to any bacterial lung infection, an application that is important when it comes to the bacterial strains involved or when the patient is sensitive to antibiotics. Lysosin has been used in patients with chronic and very acute lung infections, with complete recovery in less than 48 hours; moreover, lysosin is very useful in eliminating bacterial multiplication of viral respiratory infections. Because it does not produce any type of side effects, lysosin is the best option for patients who are immunocompromised or undergoing chemotherapy.

[0171] Use the program. The most effective way to deliver the lysosin formulation to the lungs is through a nebulizer. One dose (100 mg) dissolved in distilled water or saline solution proved to be highly effective (full recove...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A broad spectrum antimicrobial formulation comprising lysozyme and a method of treatment for preventing or curing bacterial etiological diseases. The excipient provided in the pharmaceutical formulation comprising the lysozyme enhances the stability and efficacy of the lysozyme in the treatment of bacterial infections in mammals. Pharmaceutical formulations comprising lysozyme do not produce harmful secondary effects on tissues or organs during long-term treatment. The formulations can be used to treat bacterial infections in skin, mucosal regions, and can be administered to the blood flow of a patient, including respiratory tract infections. The formulations are useful in the treatment of bacterial infections, including those occurring with viral infections, especially viral infections with respiratory tract components, including COVID-19.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 853,215, filed May 28, 2019. It is hereby incorporated by reference into this application in its entirety. technical field [0003] The present invention generally relates to broad spectrum bactericidal formulations for use in the treatment or prevention of bacterial infections in mammals, including bacterial infections associated with viral infections. The invention also includes a method of treating a bacterial infection in a mammal by administering a pharmaceutical composition of the invention to the affected area of ​​the mammal. Background technique [0004] The following presents background information on certain aspects of the invention as they may relate to technical features mentioned in the detailed description, but not necessarily in detail. That is, certain components of the invention may be described in greater detail in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/04
CPCA61K38/47A61K9/0078A61K47/02A61K47/183A61K9/0056A61K9/0019
Inventor 第欧根尼·艾巴尔-巴蒂斯塔
Owner AYBAR ECOTECHNOLOGIES CORP